Baker Avenue Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Baker Avenue Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$580K	Sell	931 -130	-12%	-$88.5K	0.01%	446
2026 Q1	$819K	Buy	1,061 +678	+177%	+$519K	0.02%	308
2025 Q4	$295K	Sell	383 -465	-55%	-$316K	0.01%	507
2025 Q3	$477K	Buy	848 +229	+37%	+$129K	0.01%	361
2025 Q2	$325K	Sell	619 -28	-4%	-$15.6K	0.01%	365
2025 Q1	$410K	Sell	647 -3	-0.5%	-$2.06K	0.01%	323
2024 Q4	$463K	Sell	650 -23	-3%	-$19.3K	0.01%	299
2024 Q3	$707K	Buy	+673	New	+$749K	0.02%	256
2023 Q4	–	Sell	-44	Closed	-$36.2K	–	1230
2023 Q3	$36.2K	Buy	44 +1	+2%	+$786	﹤0.01%	564
2023 Q2	$30.9K	Sell	43 -743	-95%	-$573K	﹤0.01%	593
2023 Q1	$646K	Buy	786 +106	+16%	+$79.9K	0.03%	229
2022 Q4	$491K	Buy	+680	New	+$502K	0.03%	247

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Baker Avenue Asset Management's REGN Position: Q2 2026 in Review

Baker Avenue Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, selling an estimated $88.5K and leaving 931 shares worth $580K. The position accounts for 0.01% of the portfolio, ranked #446.

Baker Avenue Asset Management first reported a position in REGN in Q4 2022 and has held it in 12 quarters since. The position peaked at $819K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Baker Avenue Asset Management held 931 shares of Regeneron Pharmaceuticals worth $580K as of Q2 2026.
Baker Avenue Asset Management sold 130 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $88.5K.
Regeneron Pharmaceuticals made up 0.01% of Baker Avenue Asset Management's portfolio in Q2 2026, its #446 holding.
Baker Avenue Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
Baker Avenue Asset Management's Regeneron Pharmaceuticals position peaked at $819K in Q1 2026.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Baker Avenue Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.